The potential of 5-fluorocytosine/cytosine deaminase enzyme prodrug gene therapy in an intrahepatic colon cancer model

Colorectal cancer can metastasize to the liver, but remain liver confined for years. A critical step in developing treatments for intrahepatic cancer involves assessment in an orthotopic intrahepatic model. The purpose of this study was to develop a noninvasive intrahepatic tumor model to study the efficacy of 5-flucytosine/yeast cytosine deaminase (5FC/yCD)-based gene therapy for liver tumors. Luciferase expressing human colorectal carcinoma (HT-29luc) cells were generated by retroviral infection and implanted in the left liver lobe of nude mice. The bioluminescence was measured every week for a period of 1 month, then animals were killed and tumors were measured by calipers. After we found a correlation between photon counts and tumor size, animals were implanted with tumors composed of either 0%, 10%, or 100% yCD/HT-29luc cells, and treated with 5FC. Tumor bioluminescence was measured during treatment and tumor histology examined at the time of death. We found that 5FC caused significant regression of yCD expressing tumors. Furthermore, visible tumors at the time of death, which emitted little bioluminescence, contained little or no viable tumor. We then developed an adenoviral vector for yCD. Intraperitoneal administration of adenovirus containing yCD led to the production of yCD enzyme within intrahepatic tumors. These results suggest that (1) intrahepatic cancer responds to 5FC when cells express yCD; (2) the luciferin–luciferase system permits non-invasive real time imaging of viable intrahepatic cancer; and (3) this system can be used to carry out gene therapy experiments using yCD adenovirus.

[1]  E. Austin,et al.  A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. , 1993, Molecular pharmacology.

[2]  A. Rehemtulla,et al.  Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. , 1999, Human gene therapy.

[3]  Daniel E. Hall,et al.  Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. , 2000, Neoplasia.

[4]  R. Diasio,et al.  Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora , 1986, Antimicrobial Agents and Chemotherapy.

[5]  R. Crystal,et al.  Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver. , 1996, Human gene therapy.

[6]  A. Rehemtulla,et al.  Yeast cytosine deaminase improves radiosensitization and bystander effect by 5-fluorocytosine of human colorectal cancer xenografts. , 2000, Cancer research.

[7]  C. Contag,et al.  Use of reporter genes for optical measurements of neoplastic disease in vivo. , 2000, Neoplasia.

[8]  H. Shimada,et al.  Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[9]  A. Rehemtulla,et al.  Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy , 2000, Gene Therapy.

[10]  I. Fidler.  Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of metastasis , 1991, Cancer and Metastasis Reviews.

[11]  S. Woo,et al.  Gene therapy of metastatic colon carcinoma: Regression of multiple hepatic metastases by adenoviral expression of bacterial cytosine deaminase , 2000, Cancer Gene Therapy.

[12]  A. Rehemtulla,et al.  Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy in colon cancer xenografts. , 1999, Cancer research.

[13]  S. Freytag,et al.  Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  R. Crystal,et al.  In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. , 1995, Human gene therapy.

[15]  R. Diasio,et al.  Evidence for Conversion of 5-Fluorocytosine to 5-Fluorouracil in Humans: Possible Factor in 5-Fluorocytosine Clinical Toxicity , 1978, Antimicrobial Agents and Chemotherapy.

[16]  T. Lawrence,et al.  The effect of single versus double-strand substitution on halogenated pyrimidine-induced radiosensitization and DNA strand breakage in human tumor cells. , 1990, Radiation research.

[17]  J. Trosko,et al.  Preferential cytotoxicity of cells transduced with cytosine deaminase compared to bystander cells after treatment with 5-flucytosine. , 1998, Cancer research.

[18]  R. Crystal,et al.  Regional ‘pro-drug’ gene therapy: intravenous administration of an adenoviral vector expressing the E. coli cytosine deaminase gene and systemic administration of 5-fluorocytosine suppresses growth of hepatic metastasis of colon carcinoma , 1998, Gene Therapy.

[19]  R. Blaese,et al.  Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Chinnaiyan,et al.  High and selective expression of yeast cytosine deaminase under a carcinoembryonic antigen promoter-enhancer. , 2002, Cancer research.